clinical trial · NCT02527681
Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics
Basilea Pharmaceutica·phase1·terminated·n = 15
Bacterial InfectionsCeftobiprole medocaril
brief summary
This study characterized the pharmacokinetics and safety of a single dose of ceftobiprole in neonates and infants aged ≤ 3 months.
started
Nov 22, 2016
primary completion
Feb 25, 2020
completion
Feb 25, 2020
last updated
Jun 5, 2023
official title
An Open-label Study to Evaluate the Single-dose Pharmacokinetics and Safety of Ceftobiprole in Neonate and Infant Subjects Aged up to 3 Months Undergoing Treatment With Systemic Antibiotics
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol